

Dudley Robinson, Frcog

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4731722/publications.pdf>

Version: 2024-02-01

105
papers

2,608
citations

293460

24
h-index

242451

47
g-index

169
all docs

169
docs citations

169
times ranked

2336
citing authors

#	ARTICLE	IF	CITATIONS
1	International Urogynaecology Consultation chapter 1 committee 4: patients'™ perception of disease burden of pelvic organ prolapse. International Urogynecology Journal, 2022, 33, 189-210.	0.7	11
2	Shifting the treatment paradigm in idiopathic overactive bladder. International Journal of Clinical Practice, 2021, 75, e13847.	0.8	4
3	Erosion of an intrauterine contraceptive device into the urinary bladder: A case report. Case Reports in Women's Health, 2021, 29, e00274.	0.2	4
4	Defining nocturnal polyuria in women. Neurourology and Urodynamics, 2021, 40, 265-271.	0.8	3
5	Pharmacists'™ knowledge regarding the management of overactive bladder in elderly women. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 258, 269-272.	0.5	0
6	Modern management of genitourinary syndrome of menopause. Faculty Reviews, 2021, 10, 25.	1.7	10
7	A randomized, placebo-controlled clinical development program exploring the use of litoxetine for treating urinary incontinence. Neurourology and Urodynamics, 2021, 40, 1515-1523.	0.8	4
8	Healthcare professional's™ choice for surgical management of stress urinary incontinence in a U.K. tertiary hospital. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 263, 7-14.	0.5	3
9	Anticholinergic therapy: A case-based approach. Case Reports in Women's Health, 2020, 25, e00164.	0.2	1
10	Practice observed in managing gynaecological problems in post-menopausal women during the COVID-19 pandemic. Post Reproductive Health, 2020, 26, 227-228.	0.3	3
11	An unusual late complication with tension-free vaginal tape (TVT): A case report. Case Reports in Women's Health, 2020, 28, e00252.	0.2	1
12	<p>Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder</p>. Clinical Interventions in Aging, 2020, Volume 15, 1493-1503.	1.3	30
13	The use of 3D ultrasound in comparing surgical techniques for posterior wall prolapse repair: a pilot randomised controlled trial. Journal of Obstetrics and Gynaecology, 2020, 41, 1-7.	0.4	1
14	The cognitive safety of antimuscarinics in the treatment of overactive bladder. Expert Opinion on Drug Safety, 2020, 19, 1303-1313.	1.0	2
15	Vaginal mesh: What lessons have we learnt?. Case Reports in Women's Health, 2020, 28, e00258.	0.2	3
16	Urethral bulking agent found in a urethral caruncle which did not respond to topical oestrogens: A case report. Case Reports in Women's Health, 2020, 28, e00268.	0.2	0
17	Is there enough evidence to justify the use of laser and other thermal therapies in female lower urinary tract dysfunction? Report from the ICI's 2019. Neurourology and Urodynamics, 2020, 39, S140-S147.	0.8	6
18	What affects the placebo effect?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 246, 134-137.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Recent advances in managing overactive bladder. F1000Research, 2020, 9, 1125.	0.8	14
20	Recent advances in urodynamics in women. F1000Research, 2020, 9, 606.	0.8	1
21	Time for a botulinum toxin passport?. Neurourology and Urodynamics, 2020, 39, 2546-2549.	0.8	1
22	Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment. European Urology, 2019, 76, 767-779.	0.9	19
23	Management of nocturia: overcoming the challenges of nocturnal polyuria. British Journal of Hospital Medicine (London, England: 2005), 2019, 80, 517-524.	0.2	3
24	Can we replace the catheter when evaluating urinary residuals?. Neurourology and Urodynamics, 2019, 38, 1100-1105.	0.8	3
25	The Role of Local Hormone Replacement in Overactive Bladder. Current Bladder Dysfunction Reports, 2019, 14, 342-349.	0.2	0
26	Do we need better information to advise women with stress incontinence on their choice of surgery? Report from the ICIâ€RS 2018. Neurourology and Urodynamics, 2019, 38, S98-S103.	0.8	1
27	Is our current understanding and management of nocturia allowing improved care? International Consultation on Incontinenceâ€Research Society 2018. Neurourology and Urodynamics, 2019, 38, S127-S133.	0.8	3
28	Longâ€term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourology and Urodynamics, 2019, 38, 779-792.	0.8	13
29	Prevalence and predictors of overactive bladder in nonpregnant nulliparous women below 65Âyears of age. International Urogynecology Journal, 2018, 29, 531-537.	0.7	3
30	Cardiovascular Safety of the Î² ₃ -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. Journal of Clinical Pharmacology, 2018, 58, 1084-1091.	1.0	15
31	A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects. Blood Pressure Monitoring, 2018, 23, 153-163.	0.4	9
32	Patientâ€reported outcomes from SYNERGY, a randomized, doubleâ€blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics, 2018, 37, 394-406.	0.8	33
33	Laparoscopic mesh repair of a labial hernia. Neurourology and Urodynamics, 2018, 37, 1178-1179.	0.8	0
34	Narrated video demonstrating the procedure of videourodynamics. Neurourology and Urodynamics, 2018, 37, 1176-1177.	0.8	2
35	Post-hysterectomy vaginal vault prolapse. Maturitas, 2018, 107, 39-43.	1.0	24
36	Neuromodulation for refractory overactive bladder in men. Trends in Urology & Men's Health, 2018, 9, 21-25.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Expert Opinion on Three Clinical Cases with a Common Urgent Problem: Urge Urinary Incontinence. Case Reports in Urology, 2018, 2018, 1-6.	0.1	1
38	Does assessing urethral function allow the selection of the optimal therapy for recurrent SUI? Report from the ICIâ€RS 2017. Neurourology and Urodynamics, 2018, 37, S69-S74.	0.8	2
39	6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: EVALUATION AND TREATMENT OF URINARY INCONTINENCE, PELVIC ORGAN PROLAPSE AND FAECAL INCONTINENCE. Neurourology and Urodynamics, 2018, 37, 2271-2272.	0.8	484
40	Managing nocturia: The multidisciplinary approach. Maturitas, 2018, 116, 123-129.	1.0	9
41	Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY) Tj ETQq1 1007843148gBT /Ove		
42	Is there any association between urodynamic variables and severity of overactive bladder in women with idiopathic detrusor overactivity?. Neurourology and Urodynamics, 2017, 36, 780-783.	0.8	10
43	Eroded Tape: A Case of an Early Vesicoscopy Rather Than Laser Melting. Urology, 2017, 102, 247-251.	0.5	5
44	Anticholinergic prescription: are healthcare professionals the real burden?. International Urogynecology Journal, 2017, 28, 1249-1256.	0.7	22
45	Narrated video of a re-do colposuspension. Neurourology and Urodynamics, 2017, 36, 1427-1428.	0.8	0
46	Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (<scp>SYNERGY</scp> study). BJU International, 2017, 120, 562-575.	1.3	132
47	Are we justified in suggesting change to caffeine, alcohol, and carbonated drink intake in lower urinary tract disease? Report from the ICIâ€RS 2015. Neurourology and Urodynamics, 2017, 36, 876-881.	0.8	38
48	Under what circumstances should stress incontinence surgery be performed at the same time as prolapse surgery? ICIâ€RS 2015. Neurourology and Urodynamics, 2017, 36, 909-914.	0.8	5
49	Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICIâ€RS 2015). Neurourology and Urodynamics, 2017, 36, 882-893.	0.8	44
50	Mesh removal after vaginal surgery: what happens in the UK?. International Urogynecology Journal, 2017, 28, 989-992.	0.7	5
51	Current evidence and emerging drug therapies for overactive bladder. Minerva Obstetrics and Gynecology, 2017, 69, 269-285.	0.5	1
52	Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study. Neurourology and Urodynamics, 2016, 35, 819-825.	0.8	16
53	Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014. Neurourology and Urodynamics, 2016, 35, 299-303.	0.8	33
54	Technical Video: Vesicoscopic Excision of Eroded Tension-free Vaginal Tape. Journal of Minimally Invasive Gynecology, 2016, 23, 676.	0.3	3

#	ARTICLE	IF	CITATIONS
55	Combined Laparoscopic, Vesicoscopic, and Vaginal Repair of a Vesicovaginal Fistula. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 859-860.	0.3	2
56	Can we predict detrusor overactivity in women with lower urinary tract symptoms? The King's Detrusor Overactivity Score (KiDOS). <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 205, 127-132.	0.5	5
57	Assessment of the impact of urogenital prolapse on sexual dysfunction. <i>Maturitas</i> , 2016, 92, 56-60.	1.0	7
58	Current and future pharmacotherapy for treating overactive bladder. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1317-1325.	0.9	26
59	Digital assessment and quantification of pelvic organ prolapse (DPOP-Q): a randomised cross-over diagnostic agreement trial. <i>International Urogynecology Journal</i> , 2016, 27, 433-437.	0.7	5
60	A drug safety evaluation of mirabegron in the management of overactive bladder. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 689-696.	1.0	16
61	The management of urinary tract infections in octogenarian women. <i>Maturitas</i> , 2015, 81, 343-347.	1.0	17
62	Management of recurrent stress urinary incontinence after failed midurethral sling: a survey of members of the International Urogynecological Association (IUGA). <i>International Urogynecology Journal</i> , 2015, 26, 1285-1291.	0.7	31
63	What is the best surgical intervention for stress urinary incontinence in the very young and very old? An International Consultation on Incontinence Research Society update. <i>International Urogynecology Journal</i> , 2015, 26, 1599-1604.	0.7	8
64	Overactive Bladder and the β ²³ -Adrenoceptor Agonists: Current Strategy and Future Prospects. <i>Drugs</i> , 2015, 75, 1707-1713.	4.9	7
65	Is there a link between preoperative fluoroscopic cough stress testing and synthetic midurethral tape outcome?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 193, 61-64.	0.5	0
66	Patient and surgeon goal achievement 10 years following surgery for pelvic organ prolapse and urinary incontinence. <i>International Urogynecology Journal</i> , 2015, 26, 1679-1686.	0.7	16
67	Voiding difficulties in the elderly. <i>Post Reproductive Health</i> , 2014, 20, 143-147.	0.3	3
68	Prevention and management of pelvic organ prolapse. <i>F1000prime Reports</i> , 2014, 6, 77.	5.9	27
69	Urinary Incontinence in the Young Woman: Treatment Plans and Options Available. <i>Women's Health</i> , 2014, 10, 201-217.	0.7	11
70	Oestrogens and overactive bladder. <i>Neurourology and Urodynamics</i> , 2014, 33, 1086-1091.	0.8	65
71	A comparison of risk factors for women seeking labiaplasty compared to those not seeking labiaplasty. <i>Body Image</i> , 2014, 11, 57-62.	1.9	39
72	Management of prolapse in older women. <i>Post Reproductive Health</i> , 2014, 20, 30-35.	0.3	5

#	ARTICLE	IF	CITATIONS
73	Combined Vaginal and Vesicoscopic Collaborative Repair of Complex Vesicovaginal Fistulae. <i>Urology</i> , 2014, 84, 950-954.	0.5	10
74	You are what you eat: The impact of diet on overactive bladder and lower urinary tract symptoms. <i>Maturitas</i> , 2014, 79, 8-13.	1.0	21
75	Radiation exposure during videourodynamics in women. <i>International Urogynecology Journal</i> , 2013, 24, 1547-1551.	0.7	22
76	New developments in the medical management of overactive bladder. <i>Maturitas</i> , 2013, 76, 225-229.	1.0	9
77	The effect of hormones on the lower urinary tract. <i>Menopause International</i> , 2013, 19, 155-162.	1.6	121
78	The medical management of refractory Overactive Bladder. <i>Maturitas</i> , 2013, 74, 386-390.	1.0	12
79	The management of overactive bladder refractory to medical therapy. <i>Maturitas</i> , 2013, 75, 101-104.	1.0	13
80	Antimuscarinic drugs to treat overactive bladder. <i>BMJ: British Medical Journal</i> , 2012, 344, e2130-e2130.	2.4	28
81	Overactive bladder: Diagnosis and management. <i>Maturitas</i> , 2012, 71, 188-193.	1.0	24
82	Defining female voiding dysfunction: ICIERS 2011. <i>Neurourology and Urodynamics</i> , 2012, 31, 313-316.	0.8	39
83	The efficacy and safety of PSD503 (phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 159, 457-460.	0.5	10
84	Estrogens and the lower urinary tract. <i>Neurourology and Urodynamics</i> , 2011, 30, 754-757.	0.8	76
85	Measuring quality of life in urogenital prolapse. <i>Expert Review of Obstetrics and Gynecology</i> , 2010, 5, 525-532.	0.4	1
86	New drug treatments for urinary incontinence. <i>Maturitas</i> , 2010, 65, 340-347.	1.0	21
87	Three-dimensional ultrasound of the urethral sphincter predicts continence surgery outcome. <i>Neurourology and Urodynamics</i> , 2009, 28, 90-94.	0.8	46
88	Solifenacin: pharmacology and clinical efficacy. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 239-253.	1.3	8
89	Atlas of Urogynecological Endoscopy. <i>BJU International</i> , 2008, 101, 1461-1461.	1.3	0
90	Pharmacotherapy of overactive bladder syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 163-175.	1.3	1

#	ARTICLE	IF	CITATIONS
91	A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. <i>BJU International</i> , 2007, 100, 840-845.	1.3	72
92	Outcome measures in urogynaecology: the clinicians' perspective. <i>International Urogynecology Journal</i> , 2007, 18, 273-279.	0.7	29
93	Overactive bladder in the female patient: The role of estrogens. <i>Current Bladder Dysfunction Reports</i> , 2007, 2, 97-103.	0.2	0
94	Pharmacological Treatment for Overactive Bladder in Women. <i>Women's Health</i> , 2006, 2, 239-250.	0.7	0
95	P-QOL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapse. <i>International Urogynecology Journal</i> , 2005, 16, 176-181.	0.7	216
96	The emerging role of solifenacin in the treatment of overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1339-1348.	1.9	11
97	Oestrogens and the lower urinary tract. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2004, 111, 10-14.	1.1	17
98	Urogenital effects of hormone therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2003, 17, 91-104.	2.2	29
99	The role of estrogens in female lower urinary tract dysfunction. <i>Urology</i> , 2003, 62, 45-51.	0.5	239
100	Risk factors for urinary incontinence in women. <i>The Journal of the British Menopause Society</i> , 2003, 9, 75-79.	1.3	6
101	Overactive bladder in the female patient: The role of estrogens. <i>Current Urology Reports</i> , 2002, 3, 452-457.	1.0	8
102	Can ultrasound replace ambulatory urodynamics when investigating women with irritative urinary symptoms?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2002, 109, 145-148.	1.1	103
103	Randomised comparison of Burch colposuspension versus anterior colporrhaphy for patients with stress urinary incontinence. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2001, 108, 128-129.	1.1	1
104	Ambulatory dynamics: do they help clinical management?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 1183-1183.	1.1	0
105	The management of urogynaecological problems in pregnancy and the postpartum period. <i>The Obstetrician and Gynaecologist</i> , 0, , .	0.2	0